FAQ: What are some best practices in determining clinically meaningful “response” to therapy for IBS-C patients?
GHAPPcast17 Sep 2024

FAQ: What are some best practices in determining clinically meaningful “response” to therapy for IBS-C patients?

Thank you to Ardelyx for your support of this FAQ Video Module.

In this episode, Kim Orleck, PA-C, discusses key strategies for evaluating treatment response in patients with IBS-C (Irritable Bowel Syndrome with Constipation). With multiple therapeutic options now available, it is essential for providers to take a patient-centered approach to ensure meaningful symptom improvement and treatment satisfaction.

A critical component of effective IBS-C management is setting realistic treatment goals and ensuring that both providers and patients align on expectations. Since bowel symptoms typically improve faster than pain and bloating, clinicians must educate patients on realistic timelines for symptom relief. Additionally, understanding which symptoms are most bothersome allows providers to focus on personalized treatment strategies that target the patient's specific concerns.

Kim Orleck emphasizes the importance of open-ended questioning, as this allows providers to gain deeper insights into the patient's experience rather than relying on simple yes/no answers. Evaluating global symptom relief, including pain, bloating, and overall quality of life, ensures a more comprehensive assessment of treatment success. With more treatment options available than ever before, it is essential that patients feel empowered to explore alternative therapies if their current treatment is not delivering optimal results.

Watch now to learn how to optimize IBS-C treatment strategies and improve patient outcomes. For more resources, visit the GHAPP website or download the GHAPP ACE mobile app on IOS or Android.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(164)

Linerixibat Medication Review

Linerixibat Medication Review

Christina Hanson, FNP, and Dr. Marcelo Kugelmas of South Denver Gastroenterology review linerixibat, an ileal bile acid transporter (IBAT) inhibitor, and its role in managing cholestatic pruritus in p...

22 Sep 13min

Podcast: Managing Fatigue and Pruritus in Your Patients With PBC

Podcast: Managing Fatigue and Pruritus in Your Patients With PBC

How can clinicians better recognize and manage itching and fatigue in primary biliary cholangitis (PBC)? In this podcast, hepatology clinicians from RUSH University Medical Center discuss the impact o...

15 Sep 15min

Podcast: How to Screen and Diagnose Cholestatic Liver Diseases

Podcast: How to Screen and Diagnose Cholestatic Liver Diseases

In this episode, HoChong Gilles of the Richmond VA Medical Center, and Alison Moe of Atlanta Gastroenterology discuss a practical, step-by-step approach to screening for and diagnosing cholestatic liv...

25 Aug 20min

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this podcast episode. In this GHAPP podcast, host Christina Hanson, FNP, welcomes Janet Gripshover, DNP, FNP-BC, MBA, for a practical discussion on recognizing ...

18 Aug 48min

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module.In this FAQ video module, Natalie Oliver, PA-C, discusses how healthcare professionals can counsel patients and caregivers about overt hep...

11 Aug 4min

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module. In this FAQ video module, Samantha Ramirez, NP-C, discusses how healthcare professionals can identify and diagnose overt hepatic encephal...

4 Aug 2min

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Thank you to Johnson & Johnson for their support on this podcast episode. In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussio...

23 Juli 7min

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Thank you to AbbVie for their support of this Medication Review Video Module.In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the...

30 Juni 17min

Populärt inom Hälsa

husmodern-med-amanda-schulman
somna-med-henrik
rss-bara-en-till-om-beroende-medberoende
rss-jossan-nina
inga-beiga-morsor
bullfika
rss-vuxna-pa-latsas
rss-viktmedicinpodden
not-fanny-anymore
sexnoveller-deluxe
angestpodden
sa-in-i-sjalen
rss-hos-psykologen
johannes-hansen-podcast
rss-ronden
sova-med-dan-horning
rss-i-skallen-pa
tyngre-traningssnack
tyngre-radio
rss-lattsamt-med-kp